Geode Capital Management
MAIA icon

Geode Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Geode Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
360,481
+63,741
+21% +$118K ﹤0.01% 3582
2025
Q4 		$454K Buy
296,740
+25,684
+9% +$33.5K ﹤0.01% 3616
2025
Q3 		$418K Buy
271,056
+48,873
+22% +$79.8K ﹤0.01% 3686
2025
Q2 		$400K Buy
222,183
+7,746
+4% +$13.9K ﹤0.01% 3627
2025
Q1 		$328K Buy
214,437
+16,913
+9% +$31.3K ﹤0.01% 3690
2024
Q4 		$391K Buy
197,524
+4,961
+3% +$11.9K ﹤0.01% 3685
2024
Q3 		$541K Buy
192,563
+35,821
+23% +$112K ﹤0.01% 3559
2024
Q2 		$536K Buy
156,742
+103,485
+194% +$326K ﹤0.01% 3547
2024
Q1 		$117K Buy
53,257
+8,700
+20% +$13.1K ﹤0.01% 4113
2023
Q4 		$52.2K Hold
44,557
– – ﹤0.01% 4340
2023
Q3 		$98.1K Buy
44,557
+10,570
+31% +$20.9K ﹤0.01% 4260
2023
Q2 		$74.8K Buy
+33,987
New +$90.9K ﹤0.01% 4420

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management's MAIA Position: Q1 2026 in Review

Geode Capital Management increased its MAIA Biotechnology (MAIA) stake by 21% in Q1 2026, buying an estimated $118K and bringing the position to 360,481 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #3582.

Geode Capital Management first reported a position in MAIA in Q2 2023 and has held it in 12 quarters since. The position peaked at $541K in Q3 2024. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

  • Geode Capital Management held 360,481 shares of MAIA Biotechnology worth $505K as of Q1 2026.
  • Geode Capital Management bought 63,741 MAIA Biotechnology shares in Q1 2026, an estimated $118K.
  • MAIA Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3582 holding.
  • Geode Capital Management first reported a position in MAIA Biotechnology in Q2 2023 and has held it in 12 quarters since.
  • Geode Capital Management's MAIA Biotechnology position peaked at $541K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.